Navigation Links
Start of Phase IIa Study in Acute Lung Injury Patients Marks Development Milestone
Date:12/19/2011

VIENNA, December 19, 2011 /PRNewswire/ --

APEIRON Biologics AG (Apeiron) announced today that GlaxoSmithKline (GSK), exclusive, worldwide licensee for Apeiron's new investigational recombinant human Angiotensin Converting Enzyme 2 (rhACE2, name: GSK2586881, formerly APN01), has initiated a phase IIa study in patients suffering from Acute Lung Injury.

Apeiron today announced the initiation of a phase IIa clinical study of rhACE2, in patients with Acute Lung Injury (ALI). The study, of which Apeiron's licensee GSK is sponsor, will include subjects with a positive diagnosis of ALI, and will be conducted in the intensive care units of multiple hospitals throughout the United States and Canada.

ALI is an acute, severe injury to the lungs associated with a variety of underlying conditions, such as sepsis, aspiration of acidic gastric contents, trauma, postoperative complications, acute pancreatitis, and pneumonia. According to recent studies, it annually affects hundreds of thousands of individuals worldwide. There are currently no pharmaceutical therapies available to treat this life-threatening condition. The most severe form of ALI, the Acute Respiratory Distress Syndrome (ARDS) has a mortality rate of over 20-40%. The efficacy of GSK2586881 has been tested in several preclinical animal models of ALI/ARDS. A phase I study in healthy volunteers also investigated the safety, tolerability and pharmacology profile of this investigational medicine.  In January 2010, GSK acquired an exclusive, worldwide license to further develop and commercialize GSK2586881 in a deal worth up to EUR 230 Mio, subject to reaching future development milestones in multiple indications.

Hans Loibner, CEO of Apeiron stated: "We are excited to see our innovative biologic APN01, after only 6 years in development, now being tested by our licensee GSK in a multicentric phase II study in ALI patients. The study is designed to provide important information regarding the safety and pharmacologic profile of this recombinant enzyme in this severely diseased patient population, as well as first insights into its clinical efficacy. This event is an important milestone for our company and validates our efforts to clinically advance novel therapies for severe conditions where there is significant unmet medical need."

About Apeiron (as of December 2011):

Apeiron is a privately financed biotech based in Vienna, Austria. Apeiron focuses on biological and immunological treatments against cancer and related conditions. Apeiron's project portfolio consists of five projects under clinical evaluation, and several preclinical projects. Clinical projects include the immunocytokine hu14.18-IL2 (APN301) that recently entered into phase II (for certain neuroblastoma patients) and is also being clinically tested against melanoma.

A liposomal formulation of recombinant human Superoxide Dismutase (APN201) is also in the clinical stage of development to prevent or treat skin damage due to radiation treatment in cancer. Recombinant human Angiotensin Converting Enzyme 2 (GSK2586881, formerly APN01), was licensed to GlaxoSmithKline in early 2010. Apeiron presently employs 25 people and has been in operation since 2006.

Contact Apeiron:
Dr. Hans Loibner, CEO    
Campus-Vienna-Biocenter 5
1030 Vienna, Austria
T +43(0)1-865-6577
E apeiron@apeiron-biologics.com
W http://www.apeiron-biologics.com

Copy Editing & Distribution:
PR&D - Public Relations for Research & Education
Mariannengasse 8
1090 Vienna, Austria
T +43(0)1-505-70-44
E contact@prd.at
W http://www.prd.at


'/>"/>
SOURCE APEIRON Biologics AG
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Mexican State of Tamaulipas Starts Training Doctors in Sangui Wound Management
2. Global Cleantech Cluster Association Names New York City Startup Rentricity to Global Top 10 List
3. Garage Start-ups Now Possible in Life Sciences Industry
4. Angioslide Named One of Israels Top Ten Most Promising Startups of 2011
5. False starts can sneak by in womens sprinting
6. Good Start Genetics™ Announces Validation Results for its Next-Generation DNA Sequencing Platform for Genetic Disorder Carrier Screening
7. ViiV Healthcare Starts Phase III Clinical Programme of Celsentri/Selzentry® (maraviroc) versus Truvada® (tenofovir + FTC), in combination with a Protease Inhibitor in people living with HIV
8. Midwest Health Care Startups Raise $315 Million in First Half of 2011
9. Start of in-Patient Clinical Trials With NT-KO-003, the First Neuroprotective Drug for Multiple Sclerosis Without Immunosuppressive Effects
10. Convergence Pharmaceuticals Announces Start of Phase II Study for its Selective Nav 1.7 blocker CNV1014802
11. BioNeutral Starts Commercial Deployment of Its Ygiene 206 Sterilant and Ogiene Products Within Port Authority Facilities Using T.U.C.S. Cleaning Services
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... --  BioInformant announces the February 2016 release of ... Tools, and Technologies – Market Size, Segments, Trends, and ... The first and only market research ... has more than a decade of historical information on ... cell type. This powerful 175 page global strategic report ...
(Date:2/10/2016)... , Febr. 10, 2016 /PRNewswire/ - BioAmber Inc. (NYSE: ... to announce that Mitsui & Co. Ltd., its partner ... acid plant, is investing an additional CDN$25 million in ... its stake from 30% to 40%.  Mitsui will also ... acid produced in Sarnia , providing ...
(Date:2/10/2016)... , Feb.10, 2016 ASAE is introducing a ... Management Companies (AMC) the option of joining or renewing ... fee determined by staff size, every employee in any ... ASAE and reap all available member benefits.   ... new organizational membership options will allow organizations of any ...
(Date:2/10/2016)... BOSTON , Feb. 10, 2016  Matchbook, ... sourcing for fast growing biotech companies, announced today ... Senior Procurement Strategic Advisor. Jim brings nearly 25 ... sourcing and procurement, having spent nearly two decades ... Supply Chain/Logistics and Procurement at Genzyme and, most ...
Breaking Biology Technology:
(Date:2/2/2016)... RESTON, Va. , Feb. 2, 2016 /PRNewswire/ ... contract award from the U.S. Army Research Office ... extend the range and sensitivity of the company,s ... DoD,s Past Accounting Mission and, more generally, defense-related ... its DNA phenotyping capabilities (predicting appearance and ancestry ...
(Date:1/28/2016)... Jan. 28, 2016 Synaptics (NASDAQ: SYNA ), a ... its second quarter ended December 31, 2015. ... of fiscal 2016 increased 2 percent compared to the comparable quarter ... of fiscal 2016 was $35.0 million, or $0.93 per diluted share. ... income for the first quarter of fiscal 2016 grew 9 percent ...
(Date:1/22/2016)... , Jan. 22, 2016 ... the addition of the "Global Biometrics ... to their offering. --> ... the "Global Biometrics Market in Retail ... --> Research and Markets ...
Breaking Biology News(10 mins):